Overall, since metastatic-endometrial carcinomas and NEEC express AR, this may serve as a potential therapeutic target for these patients based on the historical targeted treatment of male prostate and female breast cancers with anti-androgen/AR agents [6–9]. This evidence concerns the gene AR and endometrial carcinoma.